Literature DB >> 11860308

Morphologic spectrum of estrogen receptor-negative breast carcinoma.

Richard Scawn1, Sami Shousha.   

Abstract

CONTEXT: Estrogen receptor (ER)-negative breast carcinomas are a heterogeneous group of breast cancers that are generally thought to be aggressive.
OBJECTIVE: To determine the morphologic and immunohistochemical spectrum of a consecutive series of ER-negative breast carcinomas, in an attempt to understand the pathogenesis and behavior of these lesions.
DESIGN: Seventy-four consecutive cases of ER-negative invasive carcinomas were studied. Hematoxylin-eosin-stained sections were reviewed, and new sections were stained for c-erbB-2, p53, vimentin, and androgen and prolactin receptors. The findings were correlated with the axillary lymph node status as a measure of tumor aggressiveness.
SETTING: The histopathology department of a tertiary referral teaching hospital.
RESULTS: The tumors included 50 (68%) invasive ductal carcinomas, 21 (28%) medullary/atypical medullary carcinomas, and 1 each of invasive lobular, apocrine, and papillary carcinoma. Some of the invasive ductal cases had distinctive features that are described in this report. Maximum tumor diameter varied between 5 and 100 mm. Sixty tumors (81%) were grade 3, 13 (18%) were grade 2, and 1 (1%) was grade 1. Of the 60 cases in which the axillary node status was known, 34 (57%) had metastases, and 26 did not. Tumors associated with positive nodes were significantly larger than those associated with negative nodes (37.2 vs 17.8 mm, P <.001). A higher percentage of node-negative tumors were c-erbB-2 positive (42% vs 21%, P <.05). There were no differences between the 2 groups with regard to histologic type, tumor grade, or the expression of p53, vimentin, or androgen or prolactin receptors.
CONCLUSIONS: Many ER-negative breast carcinomas have distinctive microscopic features. Not all ER-negative tumors are aggressive, as judged by the absence of lymph node metastases in 43% of cases in this series. Tumor size is the most important indicator for the likelihood of the presence of lymph node metastases. The wide range of tumor sizes encountered in this series suggests that the ER status of a tumor is determined early in its natural history and supports the existence of 2 separate pathways for the development of ER-negative and ER-positive breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11860308     DOI: 10.5858/2002-126-0325-MSOERN

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer.

Authors:  V Dutta; G S Chopra; K Sahai; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Authors:  Socorro María Rodríguez-Pinilla; David Sarrió; Emiliano Honrado; Gema Moreno-Bueno; David Hardisson; Francisco Calero; Javier Benítez; José Palacios
Journal:  J Clin Pathol       Date:  2006-11-14       Impact factor: 3.411

3.  Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.

Authors:  Donata Micello; Alessandro Marando; Nora Sahnane; Cristina Riva; Carlo Capella; Fausto Sessa
Journal:  Virchows Arch       Date:  2010-08-31       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.